Skip to main content

REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1428464
This article is part of the Research Topic Toward the Future Management of Patients with Chronic Lymphocytic Leukemia View all 3 articles

MANAGEMENT OF INFECTIONS FOR PATIENT TREATED WITH IBRUTINIB IN CLINICAL PRACTICE

Provisionally accepted
Claudia Baratè Claudia Baratè 1Ilaria Scortechini Ilaria Scortechini 2Sara Ciofini Sara Ciofini 3Paola Picardi Paola Picardi 4Ilaria Ageletti Ilaria Ageletti 5Federica Loscocco Federica Loscocco 6Alessandro Sanna Alessandro Sanna 7*Alessandro Isidori Alessandro Isidori 6PAOLO SPORTOLETTI PAOLO SPORTOLETTI 8*
  • 1 Independent researcher, Pisa, Tuscany, Italy
  • 2 Hematology Clinic, Marche University Hospital, Ancona, Italy
  • 3 Dipartimento di Ematologia, Ospedale universitario di Siena, Siena, Tuscany, Italy
  • 4 Mazzoni Hospital, Ascoli Piceno, Italy
  • 5 Azienda Ospedaliera Santa Maria Terni, Terni, Italy
  • 6 Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy
  • 7 Careggi University Hospital, Florence, Italy
  • 8 University of Perugia, Perugia, Italy

The final, formatted version of the article will be published soon.

    Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly transformed the therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these advancements, the disease continues to be characterized by immune dysfunction and increased susceptibility to infections, with mortality rates from infections showing no significant improvement over the past few decades. Therefore, timely prevention, recognition, and treatment of infections remains an important aspect of the standard management of a patient with CLL. A panel of hematologists with expertise in CLL met to discuss existing literature and clinical insights for the management of infectious in CLL undergoing ibrutinib treatment. Despite not being a fully comprehensive review on the topic, this work provides a set of practical recommendations that can serve as a guide to healthcare professionals who manage these patients in their daily clinical practice.

    Keywords: CLL, Ibrutinib, Infection, Recommendation, prophylaxis

    Received: 06 May 2024; Accepted: 23 Aug 2024.

    Copyright: © 2024 Baratè, Scortechini, Ciofini, Picardi, Ageletti, Loscocco, Sanna, Isidori and SPORTOLETTI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Alessandro Sanna, Careggi University Hospital, Florence, Italy
    PAOLO SPORTOLETTI, University of Perugia, Perugia, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.